IDDSI Nutritional Drink for Dysphagia Study

Malnutrition Clinical Trial

Official title:

An Evaluation of the Tolerance, Compliance, Acceptability and Safety of a New Oral Nutritional Supplement in Dysphagic Patients

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT03679078
• Other study ID #: IDDSIL2
• Status: Suspended
• Phase: N/A
• Start date: August 28, 2018
• Est. completion date: December 1, 2024

Study information

• Verified date: November 2023
• Source: Nutricia UK Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.

Description:

Dysphagia is a complex condition common in a number of diagnoses including stroke, Parkinson's disease, head and neck cancer, dementia, learning disabilities and gastric/oesophageal motility disorders.

A modified textured diet and/or fluid is considered as an effective intervention in management of dysphagia. The International Dysphagia Diet Standardisation Initiative (IDDSI) have developed a new framework around the terms and descriptors used in the management of individuals with dysphagia. Malnutrition is very common in patients with dysphagia and the use of pre-thickened oral nutritional supplements (ONS) has been found as an effective way to manage this. However, due to impairment in the swallow process, dysphagic patients require pre-thickened oral nutritional supplement to ensure safe consumption of these nutritional supplements.

40 participants, requiring a new pre-thickened oral nutritional supplement in line with the new IDDSI framework recruited from hospitals, outpatients clinics, care homes, community hospitals, community dietetic/speech and language therapy services or stroke rehabilitation units will receive the ready-to-use oral nutritional supplement for a 4 week intervention period. This study aims to primarily evaluate gastro-intestinal tolerance, with secondary outcomes including compliance, acceptability, nutrient intake, anthropometry and safety.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 40
• Est. completion date: December 1, 2024
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female

• Age = 18 years

• Patients with a requirement for = 250kcal/day from a milkshake style ONS for = 4 weeks or current users of ONS

• Patients identified to require mildly thick (IDDSI level 2) fluids.

• Patients competent to provide written informed consent and able to answer questions

• Patients able to take study ONS orally

Exclusion Criteria:

• Patients that lack capacity to provide informed consent

• Patients that are unable to take study ONS orally

• Participants with chronic renal disease requiring dialysis

• Participants with liver failure

• Participants that are pregnant or lactating

• Participation in other studies that may interfere with this study

• Participants receiving 100% total nutritional requirements from tube feeding or parenteral nutrition

• Patients with galactosaemia or lactose intolerance

• Patients receiving palliative or end of life care

Related Conditions & MeSH terms

• Deglutition Disorders
• Dysphagia
• Malnutrition

Intervention

Dietary Supplement:
• IDDSI nutritional supplement drink
ready-to-use nutritional supplement drink to be taken daily for 28 days

Locations

Country	Name	City	State
United Kingdom	Aneurin Bevan University Health Board	Caerleon
United Kingdom	Cambridge University Hospitals NHS Foundation Trust	Cambridge
United Kingdom	Dudley Group NHS Trust	Dudley
United Kingdom	Cwm Taf University Health Board	Llwynypia
United Kingdom	Croydon Health NHS Trust	London
United Kingdom	Lewisham and Greenwich NHS Foundation Trust	London
United Kingdom	Great Western Hospitals NHS Foundation Trust	Swindon
United Kingdom	Weston Area Health Trust	Weston-super-Mare

Sponsors (1)

Lead Sponsor	Collaborator
Nutricia UK Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gastrointestinal Tolerance	Gastro-intestinal tolerance will be assessed daily throughout a 3 day baseline period before starting the study ONS and at the end of each week (day 10, day 17, day 24, day 31) using a standardised GI tolerance questionnaire including questions on number of bowel movements per day, other gastrointestinal symptoms such as flatulence, bloating, burping and abdominal discomfort. Patient-reported gastrointestinal symptoms with scale range for each symptom as s scale range minimum = none, maximum = severe.; Change of symptom from baseline scale minimum = no change, maximum = worse.	Day 1, Day 2, Day 3, Day 10, Day 17, Day 24 and Day 31
Secondary	Compliance	Daily questionnaire on amount of nutritional drink prescribed and amounts actually consumed. Amount of daily ONS actually consumed scale minimum = 0%, maximum = 100%	Once during baseline period (Day 1) and then daily through intervention period (Days 4-31)
Secondary	Acceptability: Brief tick-box questionnaire	Brief tick-box questionnaire on overall liking and acceptability of product, including texture and feel of nutritional drink, flavor and ease of use. Scale minimum = dislike very much, maximum = like very much Scale minimum = very inconvenient, maximum = very convenient Scale minimum = very difficult, maximum = very easy	Day 1, Day 17, Day 31
Secondary	Anthropometry	Measurements of height and weight with Body Mass Index (BMI) calculated at baseline and end of study.	Day 1 and Day 31
Secondary	Nutrient intake	Three dietary recalls relating to the the past 24 hours of Day 1, Day 17 and Day 31 to capture all food and fluids consumed. This will subsequently be analysed in dietary software.	Day 1, Day 17 and Day 31
Secondary	Safety (Adverse events reporting)	Reporting of any adverse events that occur throughout study.	31 days.